Azetidines as MEK inhibitors for the treatment of proliferative diseases

Abstract Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as...

Full description

Saved in:
Bibliographic Details
Main Authors KOLTUN, ELENA, BUSSENIUS, JOERG, KENNEDY, ABIGAIL R, MANALO, JEAN-CLAIRE LIMUN, PETO, CSABA J, DUBENKO, LARISA, CURTIS, JEFFRY KIMO, AAY, NAING, BLAZEY, CHARLES M, COSTANZO, SIMONA, JOSHI, ANAGHA ABHIJIT, BOWLES, OWEN JOSEPH, KIM, ANGIE INYOUNG, RICE, KENNETH D, ANAND, NEEL KUMAR, TSANG, TSZE H, DEFINA, STEVEN CHARLES
Format Patent
LanguageEnglish
Published 31.01.2013
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:Abstract Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.
Bibliography:Application Number: AU20120261703